RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
about
Hypoxia-inducible factor-1 alpha is involved in RIP-induced necroptosis caused by in vitro and in vivo ischemic brain injuryBorder Security: The Role of RIPK3 in Epithelium Homeostasis.Caspase-8: not so silently deadly.The in vivo evidence for regulated necrosis.RIPK3 Restricts Viral Pathogenesis via Cell Death-Independent Neuroinflammation.RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function.Controlled detonation: evolution of necroptosis in pathogen defense.Mechanisms of RIPK3-induced inflammation.Roles of Caspases in Necrotic Cell Death.Complex Pathologic Roles of RIPK1 and RIPK3: Moving Beyond Necroptosis.Programmed cell death as a defence against infection.RIPK3 in cell death and inflammation: the good, the bad, and the ugly.Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signaling.Initiation and execution mechanisms of necroptosis: an overview.Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome.Coordinated ubiquitination and phosphorylation of RIP1 regulates necroptotic cell death.RIPK1-dependent apoptosis bypasses pathogen blockade of innate signaling to promote immune defense.Necroptosis in the periodontal homeostasis: Signals emanating from dying cells.Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.RIP3 deficiency ameliorates inflammatory response in mice infected with influenza H7N9 virus infection.RIP3 attenuates the pancreatic damage induced by deletion of ATG7.PPAR-γ Activation Prevents Septic Cardiac Dysfunction via Inhibition of Apoptosis and NecroptosisRegulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis.Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner.CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.A murder mystery in the liver: who done it and how?Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease.Necroptosis regulated proteins expression is an early prognostic biomarker in patient with sepsis: a prospective observational study.MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death.Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.RIP3 deficiency exacerbates inflammation in dextran sodium sulfate-induced ulcerative colitis mice model.RIP1 kinase activity-dependent roles in embryonic development of Fadd-deficient mice.Immunological consequences of kidney cell death.CRISPR whole-genome screening identifies new necroptosis regulators and RIPK1 alternative splicing.Death-domain dimerization-mediated activation of RIPK1 controls necroptosis and RIPK1-dependent apoptosis.Inflammatory cell death in intestinal pathologies.RIPK3 promotes kidney fibrosis via AKT-dependent ATP citrate lyase.The enhanced susceptibility of ADAM-17 hypomorphic mice to DSS-induced colitis is not ameliorated by loss of RIPK3, revealing an unexpected function of ADAM-17 in necroptosis.Phenytoin inhibits necroptosis.The Receptor Interacting Protein Kinases in the Liver.
P2860
Q33918342-95C34CBF-EF9E-4E68-BC0A-98275715B96AQ37043034-93A17918-BE92-4551-9269-3598771D98E0Q37625431-85CAA80D-E883-4202-B6C5-7E96DE516F16Q38809791-F44A854D-872E-4407-8781-717F849A93C3Q38862204-94639F5B-AA8F-4D42-8414-98A24A5B5A40Q38984566-04D45214-A985-49CC-95CB-5B6E90B9AA63Q39026526-382EBCC0-D8A2-43C4-9462-26C41414EBEFQ39038663-2FF09D48-8D35-4BA1-91FA-4E8C7D930EBCQ39041502-E2443AF9-CBD7-45B8-9465-FA9B709DD258Q39105381-D12B3532-D8F4-4E5D-B9E2-B10949C8A7B0Q39110327-6BED6148-DD14-4CDC-A7F8-FB79502DFB7EQ39277433-8AE45317-970E-4630-AF3A-2BF2BE65B539Q39285713-7B4693D2-BE8D-4D6C-BBB5-3B8FA00348B8Q39302537-6FD932F1-DEC7-4ABC-B27D-F299ED4500F0Q39443989-9FC09F9E-82EC-4BA6-86F4-0DB20842BE8AQ39495482-0443A979-A42E-421B-A087-AFF076F35E11Q40074113-D074696C-0611-4D07-A73D-548E6C4436BAQ40111437-0D57996F-5C9A-4B8F-861B-ECDF92E2DCACQ40153668-EE2EC794-8ED4-4E0C-B5CE-D647C4541E2DQ40236129-41B10F2E-3247-464A-BA37-1DACA706789CQ41335397-B738F73F-9195-4845-89DB-AA817815F80DQ41440729-91BD7F16-6B66-4877-878F-D8CBCF218A22Q41527499-5F01F784-6E58-4BC3-82D3-BA13B6D74511Q41851303-945BD655-1332-4D5F-9D4F-02083C49C9AFQ42376104-2BBA6E59-2903-4C32-8116-2D8E59D358CAQ42734482-9DAC7EE4-F458-4DC6-80F3-BE3190850C43Q46292537-2A79878F-EEBD-4E14-A769-F259EBD1A97AQ47094546-26C4887A-D931-425D-98E9-29D143D8F050Q47787256-D86FF0F8-846F-4873-9403-5468049EC518Q47843948-7C2A214D-4394-4DFD-8E75-4121A4EC81E5Q48168744-364C7DE2-2420-4326-B5A2-8DAFA8C1B93EQ48336481-5BD1BF41-1201-4DB4-B5AD-12262FB86145Q49679688-C9AEB9FF-8EBB-4137-ABFC-CBEB5056E9DAQ49958998-A8CE1658-B299-480F-844C-E56A11453535Q50026384-67F13741-9BCC-4CF9-B3B0-2066F6765333Q50062526-FC94925B-D25B-4066-8BC0-A4D415950813Q50130544-159ACF23-EEE7-4E0A-A2F9-339E5631D70EQ52645849-EF2B4891-8C2D-48FD-9D3E-423A28C4FD85Q52676399-B1D8A57F-6AB9-4B73-AE91-12600EF1BB45Q52689573-A0CE0653-C988-47E0-B3A0-37F788968666
P2860
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RIPK3 deficiency or catalytica ...... nflammation and tissue injury.
@en
RIPK3 deficiency or catalytica ...... nflammation and tissue injury.
@nl
type
label
RIPK3 deficiency or catalytica ...... nflammation and tissue injury.
@en
RIPK3 deficiency or catalytica ...... nflammation and tissue injury.
@nl
prefLabel
RIPK3 deficiency or catalytica ...... nflammation and tissue injury.
@en
RIPK3 deficiency or catalytica ...... nflammation and tissue injury.
@nl
P2093
P2860
P356
P1476
RIPK3 deficiency or catalytica ...... nflammation and tissue injury.
@en
P2093
A Maltzman
B Martin-McNulty
B S McKenzie
D L Dugger
J D Webster
P2860
P2888
P304
P356
10.1038/CDD.2016.46
P577
2016-05-13T00:00:00Z